SMN1 and proximal spinal muscular atrophy: Onasemnogene abeparvovec, a one-time single-dose intravenous infusion, was approved by the FDA in May 2019 for the treatment of pediatric patients aged ≤2 years with SMA and biallelic mutations in SMN1 [12].